ID NPA AC CVCL_0467 AS CVCL_6475 SY NPA-87; NPA'87; NPA 87; NPA87; NPA87-1; UCLA NPA-87-1; UCLA NPA871 DR BTO; BTO_0004771 DR MCCL; MCC:0000365 DR BioSample; SAMN03151835 DR cancercelllines; CVCL_0467 DR Cosmic; 685605 DR Cosmic; 686727 DR Cosmic; 849968 DR Cosmic; 886547 DR Cosmic; 918183 DR Cosmic; 928835 DR Cosmic; 931239 DR Cosmic; 990533 DR Cosmic; 1005456 DR Cosmic; 1021384 DR Cosmic; 1071908 DR Cosmic; 1094772 DR Cosmic; 1132596 DR Cosmic; 1152122 DR Cosmic; 1155264 DR Cosmic; 1155328 DR Cosmic; 1161613 DR Cosmic; 1162848 DR Cosmic; 1176608 DR Cosmic; 1699416 DR IARC_TP53; 2129 DR TOKU-E; 4068 DR Wikidata; Q54930968 RX PubMed=2551628; RX PubMed=8423216; RX PubMed=8871538; RX PubMed=11439348; RX PubMed=14522906; RX PubMed=15980887; RX PubMed=18713817; RX PubMed=20143388; RX PubMed=21868764; WW Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx CC Problematic cell line: Contaminated. Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland papillary carcinoma. CC Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00246. CC Population: Caucasian. CC Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=8423216; PubMed=14522906). CC Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072. ST Source(s): PubMed=18713817; PubMed=21868764 ST Amelogenin: X ST CSF1PO: 11 ST D13S317: 12 ST D16S539: 9,13 ST D18S51: 13,17 ST D21S11: 30 ST D3S1358: 14,16 ST D5S818: 11,12 ST D7S820: 8 ST D8S1179: 13 ST FGA: 21 ST TH01: 6,7 ST TPOX: 8,11 ST vWA: 16,18 DI NCIt; C3802; Amelanotic melanoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_1395 ! M14 SX Male AG 33Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 33 // RX PubMed=8423216; DOI=10.1172/JCI116168; PMCID=PMC330012; RA Fagin, James Alexander RA Matsuo, Keiichi RA Karmakar, Amitabha RA Chen, Dan-Lin RA Tang, Shih-Huey RA Koeffler, Harold Phillip RT "High prevalence of mutations of the p53 gene in poorly differentiated RT human thyroid carcinomas."; RL J. Clin. Invest. 91:179-184(1993). // RX PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662; RA Zhao, Mei RA Sano, Daisuke RA Pickering, Curtis R. RA Jasser, Samar A. RA Henderson, Ying C. RA Clayman, Gary L. RA Sturgis, Erich M. RA Ow, Thomas J. RA Lotan, Reuben RA Carey, Thomas E. RA Sacks, Peter G. RA Grandis, Jennifer Rubin RA Sidransky, David RA Heldin, Nils-Erik RA Myers, Jeffrey N. RT "Assembly and initial characterization of a panel of 85 genomically RT validated cell lines from diverse head and neck tumor sites."; RL Clin. Cancer Res. 17:7248-7264(2011). // RX PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569; RA Schweppe, Rebecca E. RA Klopper, Joshua Paul RA Korch, Christopher T. RA Pugazhenthi, Umarani RA Benezra, Miriam RA Knauf, Jeffrey A. RA Fagin, James Alexander RA Marlow, Laura A. RA Copland, John Alton 3rd RA Smallridge, Robert Christian RA Haugen, Bryan R. RT "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer RT cell lines reveals cross-contamination resulting in cell line RT redundancy and misidentification."; RL J. Clin. Endocrinol. Metab. 93:4331-4341(2008). // RX PubMed=2551628; DOI=10.1210/endo-125-4-1783; RA Pang, Xuan-Ping RA Hershman, Jerome Marshall RA Chung, Matt RA Pekary, A. Eugene RT "Characterization of tumor necrosis factor-alpha receptors in human RT and rat thyroid cells and regulation of the receptors by RT thyrotropin."; RL Endocrinology 125:1783-1788(1989). // RX PubMed=8871538; DOI=10.1007/BF00128960; RA Boghaert, Erwin R. RA Ain, Kenneth B. RA Taylor, Kimberly D. RA Greenberg, Victoria L. RA Fowler, Carol RA Zimmer, Stephen G. Sr. RT "Quantitative and qualitative differences in growth, invasion and lung RT colonization of an anaplastic and a papillary human thyroid cancer RT cell line in vitro and in vivo."; RL Clin. Exp. Metastasis 14:440-450(1996). // RX PubMed=20143388; DOI=10.1002/ijc.25242; RA Capes-Davis, Amanda RA Theodosopoulos, George RA Atkin, Isobel RA Drexler, Hans Gunther RA Kohara, Arihiro RA MacLeod, Roderick A.F. RA Masters, John R.W. RA Nakamura, Yukio RA Reid, Yvonne A. RA Reddel, Roger Robert RA Freshney, Robert Ian RT "Check your cultures! A list of cross-contaminated or misidentified RT cell lines."; RL Int. J. Cancer 127:1-8(2010). // RX PubMed=11439348; DOI=10.1038/sj.onc.1204531; RA Frasca, Francesco RA Vigneri, Paolo RA Vella, Veronica RA Vigneri, Riccardo RA Wang, Jean Yin-Jen RT "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile RT response to hepatocyte growth factor."; RL Oncogene 20:3845-3856(2001). // RX PubMed=14522906; RA Frasca, Francesco RA Vella, Veronica RA Aloisi, Alessandra RA Mandarino, Angelo RA Mazzon, Emanuela RA Vigneri, Riccardo RA Vigneri, Paolo RT "p73 tumor-suppressor activity is impaired in human thyroid cancer."; RL Cancer Res. 63:5829-5837(2003). // RX PubMed=15980887; DOI=10.1038/labinvest.3700306; RA Nakamura, Nobuki RA Carney, John Aidan RA Jin, Long RA Kajita, Sabine RA Pallares, Judit RA Zhang, He-Yu RA Qian, Xiang RA Sebo, Thomas Joseph RA Erickson, Lori A. RA Lloyd, Ricardo V. RT "RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid RT tumors."; RL Lab. Invest. 85:1065-1075(2005). //